Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been assigned a consensus recommendation of “Buy” from the eleven research firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.58.
Several research analysts have recently commented on the company. TheStreet upgraded AngioDynamics from a “c” rating to a “b-” rating in a report on Monday, April 16th. UBS upgraded shares of AngioDynamics from a “market perform” rating to an “outperform” rating in a report on Tuesday, April 3rd. Canaccord Genuity boosted their price objective on shares of AngioDynamics from $16.50 to $17.00 and gave the company a “hold” rating in a report on Monday, April 2nd. Zacks Investment Research lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, January 26th. Finally, BidaskClub lowered shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Thursday, February 15th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANGO. JPMorgan Chase & Co. grew its position in AngioDynamics by 958.2% in the 1st quarter. JPMorgan Chase & Co. now owns 895,414 shares of the medical instruments supplier’s stock valued at $15,447,000 after acquiring an additional 810,794 shares in the last quarter. BlackRock Inc. grew its position in AngioDynamics by 7.9% in the 1st quarter. BlackRock Inc. now owns 5,103,954 shares of the medical instruments supplier’s stock valued at $88,045,000 after acquiring an additional 373,558 shares in the last quarter. Heartland Advisors Inc. acquired a new position in AngioDynamics in the 1st quarter valued at about $5,990,000. Segall Bryant & Hamill LLC acquired a new position in shares of AngioDynamics during the fourth quarter worth about $4,495,000. Finally, Royce & Associates LP grew its position in shares of AngioDynamics by 13.8% during the fourth quarter. Royce & Associates LP now owns 1,098,817 shares of the medical instruments supplier’s stock worth $18,273,000 after buying an additional 133,660 shares in the last quarter. 96.18% of the stock is owned by institutional investors.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the consensus estimate of $0.20 by $0.05. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. The business had revenue of $83.85 million for the quarter, compared to analyst estimates of $86.13 million. equities analysts forecast that AngioDynamics will post 0.74 earnings per share for the current year.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.